RxDoctor Payments Data

Mary Griffin

Family · Pelahatchie, MSNPI 1518194265

Payments from drug & device makers

$695in general payments, 2019–2025

Across 38 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$396
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$116
  • Xeris Pharmaceuticals, Inc.$39
  • AstraZeneca$38
  • Novo Nordisk$29
  • Abbott$18
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$695 in reported general payments places this provider in the 60th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$72,401
Medicare patients
191
Services billed
2,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide53$53,195
OzempicSemaglutide57$51,380
JardianceEmpagliflozin39$34,248
EliquisApixaban59$32,785
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$23,726
LinzessLinaclotide41$21,881
MyrbetriqMirabegron32$19,552
Victoza 3-PakLiraglutide18$16,952
XareltoRivaroxaban25$16,104
VraylarCariprazine Hcl11$15,654
FarxigaDapagliflozin Propanediol27$14,785
Breo ElliptaFluticasone/Vilanterol12$7,010
SymbicortBudesonide/Formoterol Fumarate21$4,849
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen344$4,805
Albuterol Sulfate HfaAlbuterol Sulfate93$3,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$14$53,19553 claims
Novo NordiskOzempic$29$51,38057 claims
AbbVieLinzess, Vraylar, Synthroid$396$38,72874 claims
GSKTrelegy Ellipta, Breo Ellipta$16$30,73743 claims
AstraZenecaFarxiga, Symbicort$38$19,63448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,007 family providers in Mississippi.

Other family in Pelahatchie

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →